To me this report just confirms the arrogant stupidity of trying to outsmart regulators.
It was done with BV gel and the FDA, SPL never properly went head to head against metronidazole in a Phase lll trial, which was I suspect was what FDA wanted.
It was done with Viraleze in a number of ways and we still do not have TGA approval n Australia or UK approval as a COVID prophylactic.
Fairley's aversion to Phase lll trials, or her inability to organise small effective ones, is her legacy.
In the end it costs more and takes longer, as we know!
To me this report just confirms the arrogant stupidity of trying...
-
- There are more pages in this discussion • 13 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
10.5¢ |
Change
0.006(6.06%) |
Mkt cap ! $43.90M | |||
| Open | High | Low | Value | Volume |
| 10.0¢ | 10.5¢ | 10.0¢ | $42.85K | 414.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 10000 | 10.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.5¢ | 247015 | 5 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |